KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Preferred Stock Liabilities: 2020-2021

  • Recursion Pharmaceuticals' Preferred Stock Liabilities was N/A to $448.3 million in Q1 2021 from the same period last year, while for Mar 2021 it was $448.3 million, marking a year-over-year change of. This contributed to the annual value of $448.3 million for FY2020, which is N/A change from last year.
  • Recursion Pharmaceuticals' Preferred Stock Liabilities amounted to $448.3 million in Q1 2021, which was down 0.00% from $448.3 million recorded in Q4 2020.
  • In the past 5 years, Recursion Pharmaceuticals' Preferred Stock Liabilities registered a high of $448.3 million during Q4 2020, and its lowest value of $448.3 million during Q4 2020.
  • In the last 2 years, Recursion Pharmaceuticals' Preferred Stock Liabilities had a median value of $448.3 million in 2021 and averaged $448.3 million.